Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838973 | 1.00 | EPHX1 (0.48) | EPHX1CTSDCYP2D6SRCLMNA | |
| SCHEMBL727901 | 0.80 | SRC (0.56) | CTSDCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL5406283 | 0.79 | ESR1 (0.41) | CYP2D6SRCLMNAMAPK1CYP1A2 | |
| SCHEMBL27761879 | 0.77 | CYP3A4 (0.42) | CYP2D6MAPK1CYP1A2SLC6A3ADORA3 | |
| SCHEMBL170040 | 0.77 | SRC (0.67) | EPHX1CTSDCYP2D6SRCLMNA | |
| SCHEMBL3470624 | 0.76 | HPGD (0.50) | CYP2D6SRCLMNAMAPK1ALOX5 | |
| SCHEMBL31242992 | 0.75 | CYP2D6 (0.64) | EPHX1CTSDCYP2D6SRCLMNA | |
| SCHEMBL741751 | 0.75 | MEN1 (0.58) | EPHX1CTSDCYP2D6SRCLMNA | |
| SCHEMBL6838801 | 0.74 | TDP1 (0.61) | CYP2D6SRCLMNAMAPK1SMN1; SMN2 | |
| SCHEMBL27843461 | 0.74 | EPHX1 (0.42) | EPHX1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| EP-1246623-A4 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARM INC (US) | 2003-05-14 | — | — | EP | claimed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | claimed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | claimed |
| CN-1088935-A | Hemoregulatory peptides | SMITHKLINE BEECHAM CORP (US) | 1994-07-06 | — | — | CN | claimed |
| CN-1077960-A | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1993-11-03 | — | — | CN | claimed |
| CN-1055925-A | Pyridine derivate and preparation method thereof | ICI PLC (GB) | 1991-11-06 | — | — | CN | claimed |
| CN-110769821-B | Spiro indolines as IL-17 modulators | UCB生物制药有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | UCB Biopharma SRL (BE) | 2020-05-07 | — | — | US | disclosed |
| EP-3638227-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-04-22 | — | — | EP | disclosed |
| CN-110769821-A | Spirocyclic indolines as IL-17 modulators | UCB生物制药私人有限公司 | 2020-02-07 | — | — | CN | disclosed |
| WO-2018229079-A1 | SPIROCYCLIC INDOLINES AS IL-17 MODULATORS | UCB BIOPHARMA SPRL (BE) | 2018-12-20 | — | — | WO | disclosed |
| CN-1064485-A | IMIDAZOLE, TRIAZOLE AND TETRAZOLE DERIVATIVES | MERCK SHARP & DOHME (GB) | 1992-09-16 | — | — | CN | disclosed |
| CN-1054773-A | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1991-09-25 | — | — | CN | disclosed |
| CN-1040594-A | The method for making of neuropeptide tyrosine antagonist | MERRELL DOW PHARMA (US) | 1990-03-21 | — | — | CN | disclosed |
| CN-1039029-A | The synthetic lung surfactant preparation that contains fat and polypeptide | MERRELL DOW PHARMA (US) | 1990-01-24 | — | — | CN | disclosed |
| CN-88103015-A | CYCLIC ANTICOAGULANT PEPTIDES | — | 1988-12-21 | — | — | CN | disclosed |
| CN-86102877-A | The method for preparing bicyclic pyrazolidinones | — | 1986-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052076-B2 | Spirocyclic indolines as IL-17 modulators | IL17A, IL2, IL18 | EPHX1 3780/4885CTSD 2633/4885CYP2D6 1674/4885 |
| US-20200138797-A1 | Spirocyclic Indolines as IL-17 Modulators | IL17A, IL2, IL18 | EPHX1 3780/4885CTSD 2633/4885CYP2D6 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.